An international research team has identified a novel HIV antibody that targets the virus at a particularly vulnerable site and overcomes previous limitations of known antibodies. This study, led by ...

The research institute reported significant progress in developing therapeutic candidates targeting Zika virus infections, advancing towards potential treatment options.

Die eerste kliniese toetse op mense vir MIV-entstowwe teen stamme van die virus wat in Suider-Afrika in omloop is, het in ...

People in Canada have a new, less invasive way to test for HIV at home, following Health Canada's approval of an oral ...

Medical experts in Delhi NCR have observed widespread circulation of respiratory viruses, with Influenza A (H3N2) emerging as a leading driver of the current surge. This wave is characterised by ...

The Nipah virus typically manifests with flu-like symptoms, which can escalate to severe complications such as encephalitis, a serious brain infection. According to Dr. Sanjaya Senanayake, an ...

Maurice Jones-Drew shares his expert grade and breakdown of Quinshon Judkins’ rookie season, highlighting key performances, strengths, and what stood out during his first year. A must-watch analysis ...

The chronic hepatitis D virus market is expected to grow steadily, driven by a relatively small pipeline of emerging therapies. Leading candidates, such as Brelovitug from Bluejay Therapeutics and the ...

About 1 in 10 people carry genetic variants that make them particularly vulnerable to the Epstein-Barr virus (EBV), a ubiquitous pathogen that is increasingly being linked to conditions like multiple ...

An outbreak of the Nipah virus in the Indian state of West Bengal is raising concern in parts of Asia, leading some airports to implement precautionary health screenings. So far, five confirmed ...

Vir Biotechnology ( (VIR)) just unveiled an update. On December 16, 2025, Vir Biotechnology entered into a license agreement with Norgine Pharma UK Limited, granting Norgine exclusive commercial ...

Vir Biotechnology plans to give an exclusive license for the commercial rights to a chronic hepatitis delta treatment to an affiliate of Norgine. The biopharmaceutical company said Tuesday the license ...